Once-weekly glucagon-like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial)

被引：0

作者：

Li, Jilin ^{[1
,2
]}

Tian, Yu ^{[3
,4
]}

Li, Liping ^{[1
]}

Zhao, Yanyan ^{[5
]}

Yang, Shuhui ^{[6
]}

Xu, Wencan ^{[7
]}

Zhu, Dan ^{[1
]}

Ye, Junjun ^{[2
]}

Chen, Jingxian ^{[8
]}

Liu, Weiting ^{[9
]}

Xue, Haibo ^{[10
]}

Wu, Wei ^{[11
]}

Deng, Feiying ^{[7
]}

Duan, Yale ^{[12
]}

Hu, Zhizhen ^{[12
]}

Xie, Bin ^{[2
]}

Chen, Zhe-Sheng ^{[13
]}

Hou, Kaijian ^{[1
]}

机构：

[1] Shantou Univ, Sch Publ Hlth, Shantou 515000, Peoples R China

[2] Second Affiliated Hosp Shantou Univ Med Coll, Dept Cardiol, Shantou, Peoples R China

[3] Guangdong Med Univ, Huizhou Cent Peoples Hosp, Res Ctr, Huizhou, Guangdong, Peoples R China

[4] Benedictine Univ, Sch Publ Hlth, Lisle, IL USA

[5] First Affiliated Hosp Zhengzhou Univ, Dept Endocrinol & Metab, Zhengzhou 450052, Peoples R China

[6] Shantou Cent Hosp, Dept Endocrine & Metab Dis, Shantou, Peoples R China

[7] First Affiliated Hosp Shantou Univ Med Coll, Dept Neurol, Shantou, Peoples R China

[8] Shantou Univ, Med Coll, Grad Sch, Shantou, Guangdong, Peoples R China

[9] Anhui Univ Chinese Med, Sch Nursing, Hefei, Anhui, Peoples R China

[10] Binzhou Med Univ Hosp, Dept Endocrinol & Metab, Binzhou, Peoples R China

[11] Guangdong Prov Inst Publ Hlth, Guangdong Prov Ctr Dis Control & Prevent, Guangzhou, Peoples R China

[12] Jiangsu Hansoh Pharmaceut Grp Co Ltd, Dept Med Affairs, Shanghai, Peoples R China

[13] St Johns Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Queens, NY USA

来源：

MEDCOMM | 2025年 / 6卷 / 02期

关键词：

ambispective cohort study; cardiovascular; glucagon-like peptide-1 receptor agonist; myocardial infarction; polyethylene glycol loxenatide; type; 2; diabetes; PHARMACOKINETICS; LIXISENATIDE; EXENATIDE; COVID-19; SAFETY; CHINA;

D O I：

10.1002/mco2.70094

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

This study aimed to determine the effects of polyethylene glycol loxenatide (PEG-Loxe), a glucagon-like peptide-1 receptor agonist, on a three-point major adverse cardiovascular event (3P-MACE) in patients with type 2 diabetes mellitus (T2DM). The study was conducted in six tertiary hospitals in three cities in China. Large language models were used to retrospectively screen and include 12,341 patients with T2DM who had either cardiovascular disease or cardiovascular risk factors. The patients were divided into the PEG-Loxe cohort (treated with PEG-Loxe, n = 1282) and the control cohort (treated with incretin glucose-lowering agents, n = 11,059). After a median follow-up of 4.0 years, 3P-MACE occurred in 51 (4.0%) and 1263 (11.4%) patients in PEG-Loxe and control cohorts, respectively (hazard ratio [HR] 0.68, 95% confidence interval [CI] 0.49-0.94; p = 0.019). In the PEG-Loxe versus control cohorts, 21 (1.6%) versus 476 (4.3%) patients experienced nonfatal stroke (HR 0.63; p = 0.041), whereas 22 (1.7%) versus 545 (4.9%) experienced nonfatal myocardial infarction (HR 0.66; p = 0.058), and the incidence of cardiovascular death was 8 (0.6%) versus 240 (2.2%), respectively (HR 0.56; p = 0.118). We found a significantly lower incidence of first nonfatal myocardial infarction, nonfatal stroke, or cardiovascular deaths in the PEG-Loxe cohort than the control cohort.

引用

页数：10

共 39 条

[1] Sun H., Saeedi P., Karuranga S., Et al., IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045, Diabetes Res Clin Pract., 183, (2021)
[2] Mouri M., Badireddy M., Hyperglycemia, In StatPearls, (2024)
[3] Henning R.J., Type-2 diabetes mellitus and cardiovascular disease, Future Cardiol., 14, 6, pp. 491-509, (2018)
[4] Nelson A.J., Pagidipati N.J., Aroda V.R., Et al., Incorporating SGLT2i and GLP-1RA for cardiovascular and kidney disease risk reduction: call for action to the cardiology community, Circulation., 144, 1, pp. 74-84, (2021)
[5] Maselli D.B., Camilleri M., Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity, Adv Exp Med Biol., 1307, pp. 171-192, (2021)
[6] Mariam Z., Niazi S.K., Glucagon-like peptide agonists: a prospective review, Endocrinol Diabetes Metab., 7, 1, (2024)
[7] Honigberg M.C., Chang L.S., McGuire D.K., Et al., Use of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and cardiovascular disease: a review, JAMA Cardiol., 5, 10, pp. 1182-1190, (2020)
[8] Marso S.P., Bain S.C., Consoli A., Et al., Semaglutide and cardiovascular outcomes in patients with type 2 diabetes, N Engl J Med., 375, 19, pp. 1834-1844, (2016)
[9] Marso S.P., Daniels G.H., Brown-Frandsen K., Et al., Liraglutide and cardiovascular outcomes in type 2 diabetes, N Engl J Med., 375, 4, pp. 311-322, (2016)
[10] Gerstein H.C., Colhoun H.M., Dagenais G.R., Et al., Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial, Lancet., 394, 10193, pp. 121-130, (2019)

← 1 2 3 4 →